➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Medtronic
Merck
Colorcon
Boehringer Ingelheim

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,623,935

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,623,935 protect, and when does it expire?

Patent 8,623,935 protects SOLUPREP and is included in one NDA.

This patent has nine patent family members in seven countries.

Summary for Patent: 8,623,935
Title:Antimicrobial compositions
Abstract: Antimicrobial compositions are provided that include a hydroalcoholic solvent system comprising a lower C.sub.2-C.sub.5 alcohol and water; a cationic antimicrobial agent such as chlorhexidine gluconate; a hydrophobic polymer soluble in the lower alcohol; an emollient ester such as diesters of bibasic acids and triesters of citric acid; and an optional fatty component containing at least one free hydroxyl group, such as a C.sub.12-C.sub.21 fatty alcohol, a C.sub.12-C.sub.21 fatty ester, a C.sub.12-C.sub.21 fatty ether, a C.sub.12-C.sub.21 fatty amide, and combinations thereof. The compositions described herein display improved antimicrobial efficacy and improved cosmetic elegance.
Inventor(s): Hobbs; Terry R. (St Paul, MN), Asmus; Robert A. (Hudson, WI)
Assignee: 3M Innovative Properties Company (St. Paul, MN)
Application Number:12/811,184
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,623,935

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
3m Health Care SOLUPREP chlorhexidine gluconate; isopropyl alcohol SOLUTION;TOPICAL 208288-001 Aug 8, 2018 OTC Yes Yes   Start Trial   Start Trial Y FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,623,935

PCT Information
PCT FiledDecember 31, 2008PCT Application Number:PCT/US2008/088590
PCT Publication Date:July 16, 2009PCT Publication Number: WO2009/088894

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
McKesson
Express Scripts
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.